Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2019 Feb;9(1):39-46.
doi: 10.2217/nmt-2018-0034. Epub 2018 Dec 14.

Levodopa-carbidopa intestinal gel in a subgroup of patients with dyskinesia at baseline from the GLORIA Registry

Werner Poewe  1 , K Ray Chaudhuri  2 , Lars Bergmann  3 , Angelo Antonini  4
Affiliations
Observational Study

Levodopa-carbidopa intestinal gel in a subgroup of patients with dyskinesia at baseline from the GLORIA Registry

Werner Poewe et al. Neurodegener Dis Manag. 2019 Feb.

Abstract

Aim: To evaluate long-term effects of levodopa-carbidopa intestinal gel on dyskinesia burden.

Patients & methods: Posthoc analysis of the GLORIA registry assessed subgroups of advanced Parkinson's disease patients with <4 and ≥4 h/day of levodopa-induced dyskinesia at baseline.

Results & conclusions: Mean dyskinesia duration significantly (p < 0.0001) decreased by 3.5 h in patients with ≥4 h baseline dyskinesia; conversely, dyskinesia duration increased by 1.6 h in patients with <4 h baseline dyskinesia. Quality of life improved in both subgroups. Adverse drug reactions occurred at similar rates in both subgroups. Despite increases in levodopa dose, levodopa-carbidopa intestinal gel treatment led to significant and sustained reductions in dyskinesia time, severity and associated pain in advanced Parkinson's disease patients with high baseline dyskinesia burden.

Keywords: Parkinson’s disease; dyskinesia; levodopa; quality of life.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure

This study was supported by AbbVie Inc., North Chicago, IL, USA. AbbVie participated in the study design, research, data collection, analysis and interpretation of data, writing, reviewing and approving the manuscript for publication. W Poewe was a study investigator and has received compensation from AbbVie, Astra Zeneca, Teva, Novartis, BIAL, Biogen, Britannia, Neuroderm, UCB, Orion Pharma, Takeda, Roche, Zambon and Merz Pharmaceuticals (for consultancy and lecture fees in relation to clinical drug development programs for Parkinson's disease) outside the submitted work. He has also received royalties from Thieme, Wiley-Blackwell and Oxford University Press. KR Chaudhuri was a study investigator and has received honorarium from UCB, AbbVie, Britannia, Mundipharma, Boehringer Ingelheim and GSK Pharmaceuticals for lecturing at symposia. He has acted as a consultant for UCB, AbbVie, Britannia, Neuronova and Mundipharma. KRC acknowledges independent research presented in this paper partly funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. He has also received research funding from Parkinson's UK, PDNMG, EU Horizon 2020 and IMI initiative, as well as educational grants from UCB, Britannia, AbbVie, GSK Pharmaceuticals, Boehringer Ingelheim and Neuronova. In addition, he has received royalties from Oxford University Press and holds intellectual property rights for the Kings Parkinson's Pain Scale and Parkinson's Disease Sleep Scale 2. L Bergmann is an employee of AbbVie and owns stock or stock options. A Antonini was a study investigator and has received compensation for consultancy and speaker-related activities from UCB, Boston Scientific, Boehringer Ingelheim, AbbVie and Zambon. He has received research support from Mundipharma. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Medical writing support, funded by AbbVie, was provided by KM Cameron of JB Ashtin, who developed the first draft based on an author-approved outline and assisted in implementing author revisions.

Figures

<b>Figure 1.</b>
Figure 1.. Motor, nonmotor, and quality-of-life outcomes in patients with ≥4 and <4 h/day baseline dyskinesia after 24 months of LCIG treatment.
Statistics indicate improvement from baseline. *p < 0.05, **p < 0.01, ***p < 0.001. BL: Baseline; LCIG: Levodopa–carbidopa intestinal gel; PDQ 8: 8-item Parkinson's Disease Questionnaire; SD: Standard deviation; UPDRS: Unified Parkinson's Disease Rating Scale.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Mouradian MM, Heuser IJ, Baronti F, Fabbrini G, Juncos JL, Chase TN. Pathogenesis of dyskinesias in Parkinson's disease. Ann. Neurol. 1989;25(5):523–526. - PubMed
    1. Obeso JA, Olanow CW, Nutt JG. Levodopa motor complications in Parkinson's disease. Trends Neurosci. 2000;23(10 Suppl.):S2–S7. - PubMed
    1. Antonini A, Moro E, Godeiro C, Reichmann H. Medical and surgical management of advanced Parkinson's disease. Mov. Disord. 2018;33(6):900–908. - PubMed
    1. Chaudhuri KR, Poewe W, Brooks DJ. Motor and nonmotor complications of levodopa: phenomenology, risk factors, and imaging features. Mov. Disord. 2018;33(6):909–919. In press. - PubMed
    1. Nutt JG. Pharmacokinetics and pharmacodynamics of levodopa. Mov. Disord. 2008;23(Suppl. 3):S580–S584. - PubMed

Publication types

MeSH terms